- Home
- PINE vs FULC Comparison
PINE vs FULC Comparison
Compare PINE & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PINE
- FULC
- Stock Information
- Founded
- PINE 2019
- FULC 2015
- Country
- PINE United States
- FULC United States
- Employees
- PINE N/A
- FULC N/A
- Industry
- PINE Real Estate Investment Trusts
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- PINE Real Estate
- FULC Health Care
- Exchange
- PINE Nasdaq
- FULC Nasdaq
- Market Cap
- PINE 245.5M
- FULC 210.9M
- IPO Year
- PINE 2019
- FULC 2019
- Fundamental
- Price
- PINE $16.48
- FULC $3.85
- Analyst Decision
- PINE Strong Buy
- FULC Hold
- Analyst Count
- PINE 9
- FULC 9
- Target Price
- PINE $19.72
- FULC $7.63
- AVG Volume (30 Days)
- PINE 104.8K
- FULC 368.1K
- Earning Date
- PINE 02-06-2025
- FULC 02-25-2025
- Dividend Yield
- PINE 6.83%
- FULC N/A
- EPS Growth
- PINE N/A
- FULC N/A
- EPS
- PINE 0.14
- FULC N/A
- Revenue
- PINE $52,227,000.00
- FULC $80,871,000.00
- Revenue This Year
- PINE N/A
- FULC $2,823.78
- Revenue Next Year
- PINE $4.37
- FULC N/A
- P/E Ratio
- PINE $117.64
- FULC N/A
- Revenue Growth
- PINE 14.42
- FULC 2987.86
- 52 Week Low
- PINE $14.33
- FULC $2.86
- 52 Week High
- PINE $19.42
- FULC $13.70
- Technical
- Relative Strength Index (RSI)
- PINE 47.19
- FULC 47.75
- Support Level
- PINE $16.39
- FULC $3.64
- Resistance Level
- PINE $16.91
- FULC $3.94
- Average True Range (ATR)
- PINE 0.33
- FULC 0.18
- MACD
- PINE -0.00
- FULC 0.02
- Stochastic Oscillator
- PINE 42.50
- FULC 84.21
About PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate company. It owns and operates a portfolio of single-tenant commercial properties. The company's portfolio is comprised of single-tenant retail and office properties located in or in close proximity to MSAs, growth markets and other markets in the United States. Their portfolio consists of One thirty eight net leased properties located in Hundred and four markets in thirty five states. The majority of the firm's revenue includes rental revenue derived from the ownership and leasing of property.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.